InMed Pharmaceuticals Advances Alzheimer's Treatment with Cannabinoid Research

The rising prevalence of Alzheimer's disease, expected to affect nearly 13 million Americans by 2050, underscores the urgent need for innovative treatments. Current therapies primarily address symptoms without halting or reversing neuronal damage. InMed Pharmaceuticals Inc. (NASDAQ: INM) is at the forefront of exploring cannabinoid-based solutions, with its INM-901 compound demonstrating potential in preclinical studies to protect neurons and enhance cognitive functions.

Recent studies have highlighted INM-901's ability to improve memory, cognitive function, and reduce neuroinflammation, a key factor in Alzheimer's progression. The compound's interaction with CB1 and CB2 receptors, part of the endocannabinoid system, offers a novel approach to combating the disease's hallmark neuronal death. InMed's commitment to this research is further strengthened by the addition of Dr. David G. Morgan, a leading figure in neurodegenerative disease research, to its Scientific Advisory Board.

With Alzheimer's treatment costs projected to reach $1 trillion by 2050, the development of effective therapies like INM-901 could significantly alleviate the economic and social burdens of the disease. InMed's ongoing studies, including long-term behavioral research and drug formulation development, are critical steps toward bringing a much-needed treatment to market. The anticipated data read-out in the third quarter will provide further insights into INM-901's therapeutic potential.